Press & Statements

CSRxP: PASSAGE OF CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS WOULD BE POSITIVE STEPS TOWARD HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE

Dec 17, 2024

Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent Read More

CSRxP: USPTO WITHDRAWAL OF PATENT THICKET RULE ADDS TO URGENCY FOR CONGRESS TO PASS CORNYN-BLUMENTHAL

Dec 4, 2024

Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse Read More

CSRxP STATEMENT ON SENATE JUDICIARY MARKUP OF THE PREVAIL ACT

Nov 21, 2024

Congress Should Not Further Consider Misguided Proposal That Would Enable More Read More

CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN

Nov 20, 2024

Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels Read More

CSRxP JOINS FELLOW ADVOCATES FOR LOWER DRUG PRICES TO URGE HOUSE JUDICIARY COMMITTEE TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

Sep 6, 2024

Letter Encourages Lawmakers to Advance Bipartisan Solutions to Hold Big Pharma Read More